The bill creates a National Biopharmaceutical Manufacturing Center of Excellence housed under the National Institute of Standards and Technology. The NIST Director must competitively award a grant or other transaction agreement to a non‑Federal eligible entity (a public‑private partnership, an institution of higher education, or a consortia of those) to establish and operate one Center. The Center's goals include advancing biopharmaceutical manufacturing science and technology (especially for products important to national, health, or economic security), demonstrating flexible manufacturing systems, improving upstream and downstream processes, supporting good manufacturing practices and standardization, reducing supply bottlenecks, and expanding workforce training. The Director may fund facility construction, collaborative research to scale manufacturing, workforce training programs, and related research. The Center must establish intellectual property guidelines before starting operations. The Director must solicit applications within 180 days of enactment and provide reports to Congress at set milestones. The bill authorizes $120,000,000 for fiscal year 2026.
If you are a university, industry group, or public‑private partnership, the bill creates a chance to apply to host and run a national center that would receive federal funding to build facilities, run research, and train workers. If you are a student or worker, the Center is meant to support training programs and partnerships with educational and community organizations. If you are a manufacturer, the Center aims to develop and share methods and standards that could help scale production. The Director will choose one awardee and publish reports about the Center's formation and activities.
The text authorizes $120,000,000 for fiscal year 2026 to carry out the section. The bill lists types of uses for awarded funds (facility construction, research, workforce training). No publicly available information on total long‑term cost, additional yearly funding, or specific budget breakdowns beyond the FY2026 authorization.
The bill's findings and sense of Congress state that investing in biomanufacturing can help scale new medicines, reduce reliance on foreign supply chains, support national and health security, and address the main barrier to commercialization by providing flexible, affordable infrastructure. Supporters frame the Center as a way to accelerate manufacturing innovation, standardize quality and controls, and build a skilled biotechnology workforce.
No publicly available information.